User manual

(TEST INTERFERENCES)
IMPORTANT. A minority of your patients may be affected
by the following test interferences
•
Patients receiving intravenous infusion treatments containing maltose
(inc. EXTRANEAL™ or OCTAGAM™) should not be tested using Performa
blood glucose monitoring system.
•
The above-mentioned substances cause interference to glucose measurements
obtained using the Performa blood glucose monitoring system.
16
Substance Interference Limit
Interference due to treatments Therapeutic Range
Icodextrin / Maltose* > 0.38 mmol/L N/A
Treatments containing
Icodextrin / Maltose
*EXTRANEAL™
(for patients on CAPD)
*OCTAGAM™, Gammagard
(i.v. human immunoglobulin preparation)
Interference due to medical conditions Physiologic Range
Galactose > 0.44 mmol/L < 0.28 mmol/L
Lipids > 39.6 mmol/L 0.34 - 3.70 mmol/L (TRIG)
Haematocrit No effect with Haematocrits between 10% & 70%
Contra-indications
Severe dehydration, Hypotension, Shock
The recommendation from the
MHRA is that a venous sample
should be sent to the laboratory
for verification
Peripheral circulatory failure
Hyperosmolar non-ketotic coma (HONK)
Diabetic ketoacidosis (DKA)
}
IN THE EVENT OF AN
ADVERSE INCIDENT:
1. Report incident to Clinical
Advisor, Manager, DNS or
Biochemistry team.
2. Quarantine meter, test strips, QC
solution and log book. Also record
details of the serial number of the
meter, code number of the strips
and lot number of QC.
3. Check and retain the log book (i.e.
are the controls within range?).
4. Inform the local Roche Diagnostics
representative or Nurse Educator.
5. MHRA or IMB may need to be
informed.